Results 171 to 180 of about 924 (199)
Some of the next articles are maybe not open access.
American Journal of Health-System Pharmacy, 2023
Abstract Purpose Sulbactam/durlobactam is a combination antibiotic designed to target Acinetobacter baumannii, including carbapenem-resistant and multidrug-resistant strains. The objective of this study was to determine the physical compatibility of sulbactam/durlobactam solution during simulated Y ...
Victor H, Ruiz +5 more
openaire +2 more sources
Abstract Purpose Sulbactam/durlobactam is a combination antibiotic designed to target Acinetobacter baumannii, including carbapenem-resistant and multidrug-resistant strains. The objective of this study was to determine the physical compatibility of sulbactam/durlobactam solution during simulated Y ...
Victor H, Ruiz +5 more
openaire +2 more sources
The role of sulbactam-durlobactam in treating carbapenem-resistant Acinetobacter infections
Current Opinion in Infectious DiseasesPurpose of review Infections caused by multidrug-resistant Acinetobacter baumannii present a significant global health challenge. Available treatment options are limited and frequently constrained by unfavourable safety and pharmacokinetic profiles.
Bassetti, Matteo +3 more
openaire +3 more sources
Clinical Infectious Diseases
Abstract Background The treatment of carbapenem-resistant Acinetobacter baumannii/calcoaceticus complex (CRAB) presents significant treatment challenges. Methods We report the case of a 42-year-old woman with CRAB meningitis who ...
Pranita D Tamma +10 more
openaire +2 more sources
Abstract Background The treatment of carbapenem-resistant Acinetobacter baumannii/calcoaceticus complex (CRAB) presents significant treatment challenges. Methods We report the case of a 42-year-old woman with CRAB meningitis who ...
Pranita D Tamma +10 more
openaire +2 more sources
International Journal of Antimicrobial Agents
The broth microdilution method was used as a reference method to evaluate the accuracy of sulbactam-durlobactam disk diffusion method for A. baumannii.In 2023, 504 nonduplicated A. baumannii isolated from 59 hospitals in China were tested by broth microdilution (M07) and disk diffusion method (M02) (10/10 µg) according to the CLSI M100 Ed34 standard ...
Xiaolan Hong +7 more
openaire +2 more sources
The broth microdilution method was used as a reference method to evaluate the accuracy of sulbactam-durlobactam disk diffusion method for A. baumannii.In 2023, 504 nonduplicated A. baumannii isolated from 59 hospitals in China were tested by broth microdilution (M07) and disk diffusion method (M02) (10/10 µg) according to the CLSI M100 Ed34 standard ...
Xiaolan Hong +7 more
openaire +2 more sources
American Journal of Therapeutics
Background: Antimicrobial resistance (AMR) is a major health crisis specifically associated with Acinetobacter. Among different Acinetobacter species, Acinetobacter baumannii is known as the greatest culprit concerning clinical significance. Of most importance, carbapenem-resistant A.
Nino Marzella +4 more
openaire +1 more source
Background: Antimicrobial resistance (AMR) is a major health crisis specifically associated with Acinetobacter. Among different Acinetobacter species, Acinetobacter baumannii is known as the greatest culprit concerning clinical significance. Of most importance, carbapenem-resistant A.
Nino Marzella +4 more
openaire +1 more source
Sulbactam–durlobactam for Acinetobacter pneumonia
The Lancet Infectious Diseases, 2023Ammara Mushtaq, Abhinandan Anand Raman
openaire +1 more source
Sulbactam–durlobactam for infections caused by Acinetobacter baumannii–calcoaceticus complex
The Lancet Infectious Diseases, 2023Giuliano S., Sbrana F., Tascini C.
openaire +3 more sources
Infectious Disorders - Drug Targets
Background: Sulbactam-durlobactam (SUL-DUR) has been tested in vitro for its ability to gen- erate resistance in clinical isolates of Acinetobacter species. According to prior studies, combining durlobac- tam with sulbactam causes sulbactam-resistant isolates to become more active and revert to susceptibility.
Hemasri Velmurugan +4 more
openaire +2 more sources
Background: Sulbactam-durlobactam (SUL-DUR) has been tested in vitro for its ability to gen- erate resistance in clinical isolates of Acinetobacter species. According to prior studies, combining durlobac- tam with sulbactam causes sulbactam-resistant isolates to become more active and revert to susceptibility.
Hemasri Velmurugan +4 more
openaire +2 more sources
Sulbactam Sodium and Durlobactam Sodium
American Journal of Health-System Pharmacy, 2023openaire +2 more sources
ACS Infectious Diseases
Peptidoglycan synthesis is an underutilized drug target in Mycobacterium tuberculosis (Mtb). Diazabicyclooctanes (DBOs) are a class of broad-spectrum β-lactamase inhibitors that also inhibit certain peptidoglycan transpeptidases that are important in mycobacterial cell wall synthesis.
Mary Nantongo +12 more
openaire +2 more sources
Peptidoglycan synthesis is an underutilized drug target in Mycobacterium tuberculosis (Mtb). Diazabicyclooctanes (DBOs) are a class of broad-spectrum β-lactamase inhibitors that also inhibit certain peptidoglycan transpeptidases that are important in mycobacterial cell wall synthesis.
Mary Nantongo +12 more
openaire +2 more sources